After recovering from Oropouche infection, symptoms recur in about 60% of patients within a few days up to several weeks.

New RNA-based active agents reliably protect plants against the Cucumber mosaic virus (CMV), the most common virus in ...

Overriding the "Off Switch" Cells function through an intricate network of proteins, each designed for specific tasks like ...

Completed dosing of first two cohorts in Phase 1/2a REWRITE Clinical Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD); Interim ...

A child with a rare genetic disorder — spinal muscular atrophy type I — was treated prenatally for the first time. Courtesy of Jakob Owens  via Unsplash During an amniocentesis test, a long, thin ...

Brook trout may have a genetic trick up their scales when it comes to adapting, with limitations, to heat waves that threaten ...

KRRO-110 is the first RNA editing development candidate from Korro’s proprietary OPERA TM platform and is currently being evaluated in the Phase 1/2a REWRITE clinical study for AATD. Dosing of the ...

Researchers developed pig retinal organoids similar to human ones, advancing stem cell-based vision restoration and enabling ...

Nature's Toolbox (NTx), a life sciences company developing next-generation platforms for RNA and protein manufacturing, today announced the founding of its Scientific Advisory Board (SAB) with ...

Dyne Therapeutics’ DYNE-101 shows positive results in phase 1/2 ACHIEVE study. Read why DYN stock may rise with FDA approval and a $2.78B market opportunity.

BACKGROUND: Despite the high morbidity and mortality of heart failure with preserved ejection fraction (HFpEF), treatment ...